SGNT Related Analyst Ratings
-
Sagent Pharmaceuticals (SGNT) Guidance Conservative - Jefferies
-
Piper Jaffray Upgrades Sagent Pharmaceuticals (SGNT) to Overweight
-
Guggenheim Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Needham & Company Maintains a 'Buy' on Sagent Pharmaceuticals (SGNT); Getting Some Mojo Back
-
Jefferies Maintains a 'Buy' on Sagent Pharmaceuticals (SGNT); Q2 Bottoms Out; Q3 Rebound with Leuco
-
Morgan Stanley Downgrades Sagent Pharmaceuticals (SGNT) to Equalweight
-
Bittersweet Comments from Needham & Co. regarding Sagent Pharmaceuticals (SGNT)
-
RBC Capital Downgrades Sagent Pharmaceuticals (SGNT) to Sector Perform
-
Sagent Pharmaceuticals, Inc. (SGNT) halted, news pending
-
Needham & Company Upgrades Sagent Pharmaceuticals (SGNT) to Buy; Compelling Re-Entry Ahead of Expected 2H Growth
-
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Results On the Short Side of Expectations
-
Piper Jaffray Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Piper Jaffray Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Auriga Starts Sagent Pharmaceuticals (SGNT) at Buy
-
Needham & Company Maintains a 'Hold' on Sagent Pharmaceuticals (SGNT); Impressive Q4, But Shares Fairly Valued
-
Capstone Investments Starts Sagent Pharmaceuticals (SGNT) at Buy
-
Collins Stewart Starts Sagent Pharmaceuticals (SGNT) at Buy; Potential Earnings Upside is Underappreciated
-
Sagent Pharmaceuticals (SGNT) To Benefit From Obama's Executive Order - Jefferies
-
JPMorgan Starts Sagent Pharmaceuticals (SGNT) at Neutral
-
Jefferies Cuts Price Target & Estimates on Sagent Pharm. (SGNT), Margins Have Potential
-
Jefferies Maintains PT, Buy Rating on Sagent Pharma (SGNT); Says Generic Levaquin Will Add Modest Upside
-
Needham & Company Downgrades Sagent Pharmaceuticals (SGNT) to Hold; Valuation Call
-
Jefferies Starts Sagent Pharmaceuticals (SGNT) at Buy
-
Needham & Company Starts Sagent Pharmaceuticals (SGNT) at Buy; New Kid On The Generic Block Should More Than Just Get By
-
RBC Capital Starts Sagent Pharmaceuticals (SGNT) at Outperform
-
BofA/Merrill Lynch Starts Sagent Pharmaceuticals (SGNT) at Neutral
Back to SGNT Stock Lookup
